Evidence map›Paper›PMID 41309252›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025

[Research Progress on the Potential Mechanisms of Hyper-progressive Disease 
in Immune Checkpoint Blockade Therapy of Solid Tumors].

Tingting Liu, Kai Zhu, Jiong Deng

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tingting LiuMedical Research Center, Binzhou Medical University Hospital, Binzhou 256600, China.
Kai ZhuDepartment of Nuclear Medicine, Binzhou Medical University Hospital, Binzhou 256600, China.
Jiong DengMedical Research Center, Binzhou Medical University Hospital, Binzhou 256600, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) therapy has demonstrated significant efficacy in the treatment of various cancers. However, a subset of patients develops hyper-progressive disease (HPD) following ICB, which is characterized by accelerated tumor growth and poor clinical outcomes. This review outlines the clinical features, potential mechanisms, and possible intervention strategies of HPD, with the aim of informing clinical practice and providing relevant recommendations.
.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsAnimalsDisease ProgressionHumansImmunotherapyImmune Checkpoint InhibitorsHyper-progressive diseaseImmune checkpoint blockadeImmune escapeMetabolic reprogrammingTumor microenvironment

Identifiers

PMID41309252
PMCPMC12666421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.